Connect with us at www.abbott.com and on Twitter @AbbottNews.
Connect with us on Instagram at @AbbottGlobal. Connect with Abbott Careers on Facebook.
Abbott Social Media Terms of Use
Your use of the Abbott Laboratories ("Abbott") social media channels is subject to these Terms of Use and the terms of use of the social platform from which you accessed these Terms of Use.
The Abbott and Abbott Careers Facebook pages, @AbbottNews and @AbbottGlobal Twitter accounts, Abbott Instagram account, and Abbott YouTube channel (collectively, “social media channels”) are social media locations for community members to connect to and learn about Abbott through information, pictures and video concerning initiatives and programs. Our goal is to provide useful and interesting content about our company and foster an open and respectful dialogue relating to the specific issues and topics covered in our posts and tweets.
Abbott reserves all rights relating to the company's social media channels, including but not limited to: (i) adding, removing, or modifying any content, (ii) blocking disruptive users; and (iii) discontinuing any of our social media channels at any time. Discussion of medical and health topics should never be construed as medical advice. You are advised to contact a health care professional in your area if you need medical advice. Abbott does not represent that the information on Abbott’s social media channels is accurate, complete, reliable, useful, timely or current. You read all content at your own risk. Do not rely on the information or advice in any of these postings.
Abbott may, in its sole discretion, delete irresponsible content or content that is otherwise inconsistent with the purpose of the Abbott social media channels; namely, dissemination and sharing of on-topic, appropriate content. To the extent applicable, Abbott reserves the right to block any user that fails to follow these Terms of Use. Examples of inappropriate or off-topic messages include, but are not limited to, the following:
• Defamatory, malicious, obscene, intimidating, discriminatory, harassing or threatening comments or hate propaganda;
• Calls to violence of any kind;
• Activity that violates any law or regulation;
• Attempts to target Abbott or Abbott Followers to offer goods or services, of either a commercial or private nature;
• Spam directed at Abbott or any of Abbott’s Followers, including any form of automatically generated content or repeatedly posting the same content;
• Content that includes medical advice that may be unsolicited and/or unverified;
• Content deemed to constitute an unapproved use of any of our products or is otherwise false or misleading;
• Any potential infringement upon any intellectual property rights, including but not limited to, brand names, trade names, logos, copyrights or trade secrets of any person, business or place;
• Other content deemed to be off-topic or to disrupt the purposes of the channel, its Followers, and its sense of community and acceptance; and
• Content posted by fake or anonymous users.
Our social media channels are not the appropriate place to resolve issues, complaints or suggestions about individual sales and service experiences or our products. This does not mean we do not want to hear about such issues, but these types of concerns are best handled by trained representatives. If you’re interested in sharing comments or feedback outside the scope of these channels, you can send a message through the “Contact Us” tab on Abbott.com. Comments may be forwarded to other Abbott departments and personnel to ensure appropriate follow-up.
Please keep in mind that Abbott does not create, control, represent, nor endorse any opinions or statements expressed by others within its social media channels, including those that Follow/Like Abbott and those Followed/Liked by Abbott and that any content posted by anyone other than Abbott is the responsibility of the submitter and not Abbott. Links which take you out of our social media channels, websites, and digital assets are not under the control of Abbott, and Abbott is not responsible for the terms and conditions, privacy policy, or content of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. Also, please keep in mind that if Abbott follows another user’s account, “likes” another page, re-tweets, “favorites,” shares, or otherwise re-posts another user’s content, such an action does not constitute an endorsement.
You should understand that content you submit to our social media channels is public and will not place Abbott under any obligation to you. This means Abbott is free to disclose and use the ideas contained in content on a non-confidential basis to anyone without any liability to you. You should also not use Abbott’s social media channels to submit unsolicited ideas. Generally we don’t accept these, and if you submit any – for example by posting them – you need to understand that you don’t have ownership rights in such ideas, that we won’t compensate or reward you, and that we don’t waive any rights to use similar or related ideas previously known to us, developed by our employees, or obtained from other sources. You agree that by posting content on our social media channels, you grant us a worldwide, non-exclusive, royalty-free license (with the right to sublicense) to use, copy, reproduce, process, adapt, modify, publish, transmit and display and distribute such content in any and all media or distribution methods now known or later developed. Further, by submitting content you represent and warrant to Abbott that you are the sole owner of the content and that Abbott’s use of the content will not violate the rights of any third party, including, but not limited to copyright rights; and that you will defend and hold Abbott harmless from any and all claims arising therefrom. By submitting content you waive any right to inspect or approve of such uses and agree to hold harmless Abbott and all others identified above from any and all claims you, your heirs, executors or assigns may at any time have against Abbott on account of the granting of the license or arising out of Abbott’s use of the content.
This page is intended for a global audience. All Terms and Conditions of Facebook apply.
See these Terms of Use on the Abbott website here: http://www.abbott.com/social-media-terms-of-use.html
Investors 2
| Date | Name | Website |
| - | InterWest ... | interwest.... |
| - | WindRose H... | windrose.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.03.2011 | - | $100K | - |
Mentions in press and media 27
| Date | Title | Description |
| 30.03.2026 | Abbott Integrates Precision Oncology Portfolio into Flatiron Health’s OncoEMR to Streamline Cancer Care | What You Should Know: Integration: Abbott has partnered with Flatiron Health to natively integrate its Precision Oncology testing portfolio directly into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform. Impact: Thi... |
| 27.03.2026 | Leaders in Lab Automation: Diagnostic Companies Setting the Standard for Efficiency by Komal Garewal | Image Credit: DC Studio The pressure to deliver faster, accurate results has become a universal challenge. Efficiency and quality must go hand in hand, so as testing volumes rise and workflows grow complex, labs are implementing automation ... |
| 28.05.2025 | A New Era in Cardiac and Diabetes Care: Innovations Transforming Patient Outcomes | In the world of healthcare, innovation is the lifeblood that keeps the pulse of progress beating. Two recent breakthroughs in cardiac and diabetes care are set to redefine patient management and treatment outcomes. Abbott's dual chamber lea... |
| 22.05.2025 | Sequel Med Tech and Abbott to Integrate Future Glucose-Ketone Sensor with twiist™ AID System | What You Should Know: – Sequel Med Tech, a company developing state-of-the-art insulin delivery technologies, announced a commercial development agreement with Abbott. – The collaboration aims for the future integration of Sequel’s twiist™ ... |
| 24.10.2024 | Abbott Launches Clinical Trial to Optimize Heart Failure Treatment with AI-Powered Monitoring | What You Should Know: – Abbott, a global healthcare leader, has announced a new clinical trial, TEAM-HF, designed to improve outcomes for patients with worsening heart failure. – The first-of-its-kind trial will leverage AI and Abbott’s Car... |
| 05.09.2024 | Abbott Launches OTC Continuous Glucose Monitor, Lingo | What You Should Know: – Abbott, a global healthcare company, has announced the U.S. availability of Lingo, a continuous glucose monitoring (CGM) system designed for individuals who want to improve their overall health and wellness. – Lingo ... |
| 07.08.2024 | Abbott and Medtronic Partner to Integrate CGM System & Insulin Delivery Devices | What You Should Know: – Abbott and Medtronic announced a groundbreaking partnership to develop an integrated continuous glucose monitoring (CGM) system designed to seamlessly work with Medtronic’s automated insulin delivery (AID) and smart ... |
| 03.06.2024 | AI company Silverberry Health partners with the American Limb Preservation Society | The companies will combine Silveryberry's AI and ALPS' network to help prevent diabetic amputations One of the most common results of having diabetes is foot amputation: a quarter of the hospital admissions among diabetics are for the foot ... |
| 04.03.2024 | Rising Demand and Advancements in Europe IVD Market 2024: Assisted Reproductive Technology for Fertility Solution | Europe In Vitro Diagnostics Market 2024 Demand forin vitro diagnosticsis on therise, owing to surge in prevalence of various chronic diseases which require use of IVD tests for diagnosis PORTLAND, OREGON, UNITED STATES, March 4, 2024 /EINPr... |
| 08.02.2023 | Abbott Laboratories to Acquire Cardiovascular Systems At Equity Value of $890M | - |